Redeye initiates coverage of Qlife, which aims to bring clinical grade biomarker testing to the home...
Redeye updates its view of Egetis following a change of lead analyst and an eventful year, including...
Ecoclime växer kraftigt i Q3 men resultatet tyngs av tillträdesstädning från den just utbytta lednin...
Today, Elanders announced that it implements structural measures regarding non-profitable parts of t...
This week’s episode of ProView is on Serial Acquirers, where we dive deep into the art of building p...
Plejd är en nordisk leverantör av smart belysning, som utvecklar och producerar såväl hårdvara som m...
On the 14h of December 2022, Brain+ A/S (“Brain+” or the ”Company”) announced that the Company has s...
Redeye comments on Safeture's announcement of a partnership agreement with EMA Global, Asia's leadin...
Redeye updates its fair value range following the up to 53 design wins from a new major North Americ...
Netum issued a profit warning, lowering its EBITA-margin range.
EBIT guidance 17% below cons. for Q4'22e The previous FY'22 adj.
Redeye leaves its comments on Xbrane following today's news that the re-submission to the FDA has be...
Biovica has secured the SEK 140m new funds in growth capital and the US commercial team is also in p...
IRLAB Therapeutics has announced that the final patient has completed the treatment period and follo...
Det femåriga avtalet med Stena Recycling innebär att CirChem täcker nära 80 % av den kapacitet som a...
Kapsaicinproducenten XP Chemistries har börjat skala upp sin produktion.
Redeye comments on Mendus presenting ADVANCE II survival data at ASH 2022.
Redeye comments on today’s press release from Wyld Networks, announcing the partnership with Astroca...
Fluicell offers innovative R&D instruments for single-cell analysis and 3D bioprinting, a business a...
BioInvent had an R&D day on December 8, 2022, which provided an overview of the company’s scientific...
